12/24
12:45 pm
ew
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Low
Report
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
12/24
12:37 am
ew
Edwards Lifesciences (EW): Assessing Valuation After Recent Share Price Strength [Yahoo! Finance]
Low
Report
Edwards Lifesciences (EW): Assessing Valuation After Recent Share Price Strength [Yahoo! Finance]
12/23
09:00 am
ew
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
Low
Report
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
12/22
01:02 pm
ew
4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026 [Yahoo! Finance]
Low
Report
4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026 [Yahoo! Finance]
12/18
09:34 am
ew
Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board [Yahoo! Finance]
Low
Report
Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board [Yahoo! Finance]
12/18
08:43 am
ew
Edwards Lifesciences (NYSE:EW) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $90.00.
Low
Report
Edwards Lifesciences (NYSE:EW) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $90.00.
12/18
07:10 am
ew
Edwards Lifesciences (NYSE:EW) was given a new $100.00 price target on by analysts at Wells Fargo & Company.
Low
Report
Edwards Lifesciences (NYSE:EW) was given a new $100.00 price target on by analysts at Wells Fargo & Company.
12/18
07:05 am
ew
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/17
10:38 am
ew
Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider [Yahoo! Finance]
Low
Report
Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider [Yahoo! Finance]
12/17
10:05 am
ew
Edwards Lifesciences (NYSE:EW) was given a new $87.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Edwards Lifesciences (NYSE:EW) was given a new $87.00 price target on by analysts at Canaccord Genuity Group Inc..
12/16
07:08 am
ew
Edwards Lifesciences (NYSE:EW) was given a new $87.00 price target on by analysts at Robert W. Baird.
Low
Report
Edwards Lifesciences (NYSE:EW) was given a new $87.00 price target on by analysts at Robert W. Baird.
12/15
01:09 pm
ew
Global Interventional Cardiology Devices Market is Predicted to Cross ~USD 30 Billion by 2034, Due to the Rising Cardiovascular Disease Burden | DelveInsight [Yahoo! Finance]
Low
Report
Global Interventional Cardiology Devices Market is Predicted to Cross ~USD 30 Billion by 2034, Due to the Rising Cardiovascular Disease Burden | DelveInsight [Yahoo! Finance]
12/14
09:25 am
ew
Is There Now An Opportunity In Edwards Lifesciences Corporation (NYSE:EW)? [Yahoo! Finance]
Low
Report
Is There Now An Opportunity In Edwards Lifesciences Corporation (NYSE:EW)? [Yahoo! Finance]
12/11
07:20 am
ew
Edwards Lifesciences (NYSE:EW) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Edwards Lifesciences (NYSE:EW) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/8
07:22 am
ew
Edwards Lifesciences (NYSE:EW) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Edwards Lifesciences (NYSE:EW) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/5
07:07 pm
ew
Will Edwards Lifesciences' (EW) Upgraded 2025–2026 Outlook Reshape Its Long-Term Growth Narrative? [Yahoo! Finance]
Low
Report
Will Edwards Lifesciences' (EW) Upgraded 2025–2026 Outlook Reshape Its Long-Term Growth Narrative? [Yahoo! Finance]
12/5
11:44 am
ew
Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says [Yahoo! Finance]
Low
Report
Edwards Lifesciences' Long-term Business Outlook Appears Achievable, RBC Says [Yahoo! Finance]
12/5
10:58 am
ew
Edwards Lifesciences (NYSE:EW) was given a new $92.00 price target on by analysts at UBS Group AG.
Low
Report
Edwards Lifesciences (NYSE:EW) was given a new $92.00 price target on by analysts at UBS Group AG.
12/5
09:47 am
ew
Edwards Lifesciences (NYSE:EW) had its price target raised by analysts at Royal Bank Of Canada from $95.00 to $100.00. They now have an "outperform" rating on the stock.
Low
Report
Edwards Lifesciences (NYSE:EW) had its price target raised by analysts at Royal Bank Of Canada from $95.00 to $100.00. They now have an "outperform" rating on the stock.
12/5
08:43 am
ew
Edwards Lifesciences (NYSE:EW) was given a new $100.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Edwards Lifesciences (NYSE:EW) was given a new $100.00 price target on by analysts at Stifel Nicolaus.
12/5
08:43 am
ew
Edwards Lifesciences (NYSE:EW) was given a new $92.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Edwards Lifesciences (NYSE:EW) was given a new $92.00 price target on by analysts at Truist Financial Corporation.
12/5
08:43 am
ew
Edwards Lifesciences (NYSE:EW) was given a new $89.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Edwards Lifesciences (NYSE:EW) was given a new $89.00 price target on by analysts at Canaccord Genuity Group Inc..
12/5
08:09 am
ew
Edwards Lifesciences (NYSE:EW) had its price target raised by analysts at Robert W. Baird from $83.00 to $88.00. They now have a "neutral" rating on the stock.
Low
Report
Edwards Lifesciences (NYSE:EW) had its price target raised by analysts at Robert W. Baird from $83.00 to $88.00. They now have a "neutral" rating on the stock.
12/5
07:21 am
ew
Edwards Lifesciences (NYSE:EW) had its "hold" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
Low
Report
Edwards Lifesciences (NYSE:EW) had its "hold" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
12/5
07:21 am
ew
Edwards Lifesciences (NYSE:EW) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Edwards Lifesciences (NYSE:EW) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.